COLLPLANT BIOTECH. IS-01 Cash Flow Conversion Efficiency
COLLPLANT BIOTECH. IS-01 cash flow conversion efficiency. Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) has a cash flow conversion efficiency ratio of -0.624x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.05 Million ≈ $-3.56 Million USD) by net assets (€4.89 Million ≈ $5.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of COLLPLANT BIOTECH. IS-01 (2021–2025)
Cash flow conversion efficiency of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. This chart illustrates how COLLPLANT BIOTECH. IS-01's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for COLLPLANT BIOTECH. IS-01 for real-time trading data and today's change.
COLLPLANT BIOTECH. IS-01 Cash Flow Conversion Ratio Explained
COLLPLANT BIOTECH. IS-01 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
COLLPLANT BIOTECH. IS-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COLLPLANT BIOTECH. IS-01 ranked by their cash flow conversion efficiency. Also see COLLPLANT BIOTECH. IS-01 stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pacific Empire Minerals Corp
F:1YK
|
-0.237x |
|
TV Thunder Public Company Limited
BK:TVT
|
0.002x |
|
Firebrick Pharma Ltd
AU:FRE
|
-0.543x |
|
Cahaya Bintang Medan Tbk Pt
JK:CBMF
|
0.000x |
|
Philly Shipyard ASA
OL:PHLY
|
-4.976x |
|
Newton Golf Company
NASDAQ:NWTG
|
0.492x |
|
Fidelity Minerals Corp
V:FMN
|
-0.029x |
|
Instinct Bio Technical Company Holdings Inc. Ordinary Shares
NASDAQ:BIOT
|
N/A |
Annual Cash Flow Conversion Efficiency for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. Review CPT free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.08 Million ≈ $7.11 Million |
€-9.42 Million ≈ $-11.01 Million |
-1.549x | -47.99% |
| 2024-12-31 | €13.46 Million ≈ $15.74 Million |
€-14.09 Million ≈ $-16.48 Million |
-1.047x | -973.53% |
| 2023-12-31 | €28.34 Million ≈ $33.13 Million |
€-2.76 Million ≈ $-3.23 Million |
-0.097x | +77.02% |
| 2022-12-31 | €32.28 Million ≈ $37.74 Million |
€-13.70 Million ≈ $-16.01 Million |
-0.424x | -865.55% |
| 2021-12-31 | €45.12 Million ≈ $52.75 Million |
€2.50 Million ≈ $2.92 Million |
0.055x | -- |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more